secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-08-13T11:30:14+00:00
Accession:  0001493152-26-037575
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q2 ZEVASKYN revenue up 31% QoQ to $11.4M; net loss widens to $20.2M
--------------------------------------------------------------------------

- ZEVASKYN net revenue $11.4M in Q2 2026, up 31% QoQ from $8.7M in Q1; revenue recognized for 4 of 5 treated patients
- Net loss $(20.2)M ($0.35/share) vs $(17.1)M ($0.30/share) in Q1; cash $146.8M at June 30, down from $191.4M at Dec 31
- QTC network expanded to 7 sites; CHOP, NewYork-Presbyterian/Columbia activated in Q2, Cincinnati Children's in Q3
- CMS granted NTAP status for ZEVASKYN effective Oct 1, 2026, supporting hospital adoption and Medicare access
- R&D expenses fell to $5.0M from $9.6M (Q1 included $7.0M one-time ABO-701 in-licensing cost); SG&A $15.8M vs $19.5M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/0001493152-26-037575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer